Sponsored – Henry Schein
How pharmaceutical distribution decisions can help Community Health Centers do more for their communities

August 2–8 marks National Health Center Week, a moment to recognize the 1,500-plus Community Health Centers serving 52 million patients across more than 17,000 sites, often regardless of a patient’s ability to pay*. Behind every one of those patients is a supply chain decision most of them will never see.
Think about it: A patient walks into a CHC on a Tuesday. Maybe they are underinsured, managing a complex profile of diabetes and hypertension, and arrive at the pharmacy counter in need of three specific medications that are cost-prohibitive elsewhere. When the pharmacist hands them those medications, it isn’t a moment where care is completed, it is a moment where the clinical plan is sustained.
But what the patient doesn’t see is the complex distribution infrastructure that made that success possible. That moment at the counter was not just a transaction; it was the result of a system intentionally built to keep mission-driven care reliable, compliant, and affordable.
For CHCs, pharmaceutical distribution isn’t a back-office function. It’s a direct determinant of whether patients get the care they came for. Historically, distribution partnerships have been evaluated through the lens of transactional cost. However, finding that a more comprehensive approach, one that prioritizes operational resilience, clinical alignment, and 340B integrity, is essential to sustaining their mission. Shifting the focus total-value partnership can help ensure the supply chain remains a stable foundation for the care the community relies on every day
With patient needs that change by the hour and clinical teams that cannot afford to be distracted by administrative backorders, CHCs require a model that anticipates their reality.
“Community Health Centers measure success by whether a patient leaves with the medication they need, not by what happened behind the scenes,” says John Kropf, Director, Pharmaceutical Sales at Henry Schein Medical. “Our role is to help make sure the supply chain is never the reason care is delayed. Every distribution decision ultimately supports a patient encounter.”
That reliability is inseparable from 340B compliance. Maintaining that compliance, especially for CHCs running integrated medical and dental programs, requires a distributor built for it, not one retrofitting a general model to fit.
“Community Health Centers need a partner who understands their mission, the complexity of 340B, and the realities of serving underserved communities. When your supply chain partner understands your business, you are able to focus on what matters most: caring for patients,” says Kathleen Titus, Director, Community Health Centers & Corporate Relations at Henry Schein Medical.
Key Takeaways
- Treat supply chain as a care strategy. Reliable pharmaceutical distribution directly impacts medication access, adherence, and patient outcomes.
- Evaluate distribution partners based on reliability, service, operational resilience, and long-term value.
- Prioritize 340B expertise. Choose a partner with proven experience supporting 340B compliance and the unique operational needs of CHCs.
- Find a partner who understands CHCs. Community Health Centers require a distributor that understands their mission, patient population, and integrated care environment.
- Build relationships, not transactions. Strong distribution partnerships help reduce disruptions, strengthen operations, and allow care teams to focus on patients instead of supply chain challenges.
*Source: National Association of Community Health Centers
Looking to build a pharmaceutical strategy that supports your patients across the entire non-acute continuum of care?
Click here and connect with your Henry Schein Medical Sales Representative today to learn more.
